|
Designations:
|
SK-N-SH
|
|
Depositors:
|
G Trempe, LJ Old
|
|
Biosafety Level:
|
1
|
|
Shipped:
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
Growth Properties:
|
adherent
|
|
Organism:
|
Homo sapiens (human)
|
|
Morphology:
|
epithelial
|
|
Source:
|
Organ: brain
Disease: neuroblastoma
Derived from metastatic site: bone marrow
|
|
Cellular Products:
|
plasminogen activator
shows increased expression of M-CSF after treatment with amyloid-beta peptide
|
|
Permits/Forms:
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
Restrictions:
|
The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.
|
|
Applications:
|
transfection host (Nucleofection technology from Lonza)
|
|
Antigen expression:
|
Blood Type A; Rh+
|
|
DNA Profile (STR):
|
Amelogenin: X
CSF1PO: 11
D13S317: 11
D16S539: 8,13
D5S818: 12
D7S820: 7,10
THO1: 7,10
TPOX: 8,11
vWA: 14,18
|
|
Cytogenetic Analysis:
|
The cell line is hyperdiploid human female (XX), with the modal chromosome number of 47. Normal chromosomes N9 and N22 are single. One copy of each of these chromosomes is structurally altered to form the two marker chromosomes 9q+ and 22q+., Chromosomes N7 is trisomic. Extra bands were found on one copy of chromosome N7, thereby forming a marker chromosome as described by R.C. Seeger. May have been translocated in part(s) to the q arms of chromosomes N9 and N22.
|
|
Isoenzymes:
|
AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 1
Me-2, 2
PGM1, 1
PGM3, 1
|
|
Age:
|
4 years
|
|
Gender:
|
female
|
|
Comments:
|
The SK-N-SH line was developed by J.L. Biedler and differs from SK-N-MC (see ATCC HTB-10) in that it exhibits a longer doubling time and higher levels of dopamine - beta - hydroxylase.
SK-N-SH has been used as a target cell line in cell mediated cytotoxicity assays.
|
|
Propagation:
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
|
|
Subculturing:
|
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended
Medium Renewal: 1 to 2 times per week
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
|
|
Preservation:
|
Culture medium, 95%; DMSO, 5%
|
|
Related Products:
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003
recommended serum:ATCC 30-2020
|
|
References:
|
1191: Gilbert LC, Wachsman JT. Characterization and partial purification of the plasminogen activator from human neuroblastoma cell line, SK-N-SH. A comparison with human urokinase. Biochim. Biophys. Acta 704: 450-460, 1982. PubMed: 7052133
2154: et al., Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells established in vitro. In Vitro 8: 410, 1973.
22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
23260: Bluestein HG. Neurocytotoxic antibodies in serum of patients with systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 75: 3965-3969, 1978. PubMed: 279013
26318: Seeger RC, et al. Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res. 37: 1364-1371, 1977. PubMed: 856461
29165: Yan SD, et al. Amyloid-beta peptide-Receptor for Advanced Glycation Endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. USA 94: 5296-5301, 1997. PubMed: 9144231
32265: Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066
32287: Rostomily RC, et al. expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024
32524: Chang YE, et al. Properties of the protein encoded by the UL32 open reading frame of herpes simplex virus 1. J. Virol. 70: 3938-3946, 1996. PubMed: 8648731
32725: He B, et al. The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma134.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. J. Virol. 70: 84-90, 1996. PubMed: 8523596
32757: Yoshikawa T, et al. Downstream regulatory elements increase acute and latent herpes simplex virus type 2 latency-associated transcript expression but do not influence recurrence phenotype or establishment of latency. J. Virol. 70: 1535-1541, 1996. PubMed: 8627672
|
|
